Science
Ancient DNA Points to Origins of Indo-European Language
In 1786, a British judge named William Jones noticed striking similarities between certain words in languages, such as Sanskrit and Latin, whose speakers were separated by thousands of miles. The languages must have “sprung from some common source,” he wrote.
Later generations of linguists determined that Sanskrit and Latin belong to a huge family of so-called Indo-European languages. So do English, Hindi and Spanish, along with hundreds of less common languages. Today, about half the world speaks an Indo-European language.
Linguists and archaeologists have long argued about which group of ancient people spoke the original Indo-European language. A new study in the journal Nature throws a new theory into the fray. Analyzing a wealth of DNA collected from fossilized human bones, the researchers found that the first Indo-European speakers were a loose confederation of hunter-gatherers who lived in southern Russia about 6,000 years ago.
“We’ve been on the hunt for this for many years,” said David Reich, a geneticist at Harvard who led part of the new research.
Independent linguists had mixed reactions to the findings, with some praising their rigor and others highly skeptical.
Many decades ago, linguists began trying to reconstruct the proto-Indo-European language by looking at words shared by many different languages. That early vocabulary contained a lot of words about things like wheels and wagons, and few about farming. It looked like the kind of language that would have been spoken by nomadic herders who lived across the steppes of Asia thousands of years ago.
But in 1987, Colin Renfrew, a British archaeologist, questioned whether nomads who were constantly on the move would have stayed in any one place long enough for their language to catch on. He found it more plausible that early farmers in Anatolia (a region in what is now Turkey) spread the language as they expanded, gradually converting more and more land to farm fields and eventually building towns and cities.
The archaeologist argued that an Anatolian origin also fit the archaeological evidence better. The oldest Indo-European writing, dating back 3,700 years, is in an extinct language called Hittite, which was spoken only in Anatolia.
In 2015, two teams of geneticists — one led by Dr. Reich — shook up this debate with some remarkable data from ancient DNA of Bronze Age Europeans. They found that about 4,500 years ago, central and northern Europeans suddenly gained DNA that linked them with nomads on the Russian steppe, a group known as the Yamnaya.
Dr. Reich and his colleagues suspected that the Yamnaya swept from Russia into Europe, and perhaps brought the Indo-European language with them.
In the new study, they analyzed a trove of ancient skeletons from across Ukraine and southern Russia. “It’s a sampling tour de force,” said Mait Metspalu, a population geneticist at the University of Tartu in Estonia who was not involved in the research.
Based on these data, the scientists argue that the Indo-European language started with the Yamnaya’s hunter-gatherer ancestors, known as the Caucasus-Lower Volga people, or CLV.
The CLV people lived about 7,000 years ago in a region stretching from the Volga River in the north to the Caucasus Mountains in the south. They most likely fished and hunted for much of their food.
Around 6,000 years ago, the study argues, the CLV people expanded out of their homeland. One wave moved west into what is now Ukraine and interbred with hunter-gatherers. Three hundred years later, a tiny population of these people — perhaps just a few hundred — formed a distinctive culture and became the first Yamnaya.
Another wave of CLV people headed south. They reached Anatolia, where they interbred with early farmers.
The CLV people who came to Anatolia, Dr. Reich argues, gave rise to early Indo-European languages like Hittite. (This would also fit with the early Indo-European writing found in Anatolia.) But it was their Yamnaya descendants who became nomads and carried the language across thousands of miles.
Some experts praised the work. “It’s a very intelligent scenario that’s difficult to criticize,” said Guus Kroonen, a linguist at Leiden University in the Netherlands who was not involved in the studies.
But Dr. Metspalu hesitated to jump from the new genetic data to firm conclusions about who first spoke Indo-European. “Genes don’t tell us anything about language, period,” he said.
And Paul Heggarty, a linguist at Pontifical Catholic University of Peru, said that the DNA analysis in the study was valuable, but he rejected the new hypothesis about the first Indo-European speakers originating in Russia as “smoke and mirrors.”
In 2023, Dr. Heggarty and his colleagues published a study arguing that the first Indo-Europeans were early farmers who lived over 8,000 years ago in the northern Fertile Crescent, in today’s Middle East.
Dr. Heggarty suggested that the CLV people actually belonged to a bigger network of hunter-gatherers that stretched from southern Russia into northern Iran. Some of them could have discovered farming in the northern Fertile Crescent, and then developed the Indo-European language, which would align with his findings.
These early farmers could have given rise to Hittite speakers thousands of years later in Anatolia, he said, and later given rise to the Yamnaya. The Yamnaya brought Indo-European languages to northern and Central Europe, Dr. Heggarty argued, but they were only one part of a bigger, older expansion.
As the Indo-European debate advances, one thing is clear: Our understanding of its history now stands in stark contrast to the racist myths that once surrounded it. Nineteenth-century linguists called the original speakers of Indo-European Aryans, and some writers later pushed the notion that ancient Aryans were a superior race. The Nazis embraced the Aryan myths, using them to justify genocide.
But Dr. Reich said that studies on ancient DNA show just how bankrupt these Aryan stories were.
“There’s all sorts of mixtures and movements from places that these myths never imagined,” he said. “And it really teaches us that there’s really no such thing as purity.”
Science
Not everyone is leaving California. A new commercial battery maker just landed in Sacramento
The lithium-ion batteries that supply much of today’s clean energy come with some infamous drawbacks, from fire risk to reliance on foreign mining.
Alternatives have been slow to get off the ground.
But California startup Peak Energy announced Wednesday it’s building a factory in Sacramento that will be the first in the U.S. to make sodium-ion battery packs at commercial scale.
Sodium-ion batteries have long held promise. They are made from cheap and abundant sodium ash deposits. The materials are less prone to overheating, so they don’t have the fire risk of lithium.
But they also store less energy per cubic inch. That means they have to be bigger and heavier, which makes them harder to fit into electric vehicles. So far, they’ve struggled to compete.
Peak Energy thinks it has an edge. The company focuses on storage systems big enough to power large data centers, factories and whole segments of the grid, where battery size matters less.
The company already delivers battery packs out of a small pilot project in San Francisco, but it has gotten $1.1 billion in preorders and now needs more space.
CEO and co-founder Landon Mossburg said its first products, each about the size of a shipping container, will begin rolling out in early 2027.
“We’re a 3-year-old company with over a billion in deposit-backed customer contracts, we’ve got grid deployment already, and all those products are exceeding expectations on the grid,” Mossburg said. “Those are really great signals.”
He founded Peak after working at Tesla and the now-folded Swedish battery company Northvolt. The battery cells, which make up the systems, will come from China.
Customers for Peak who have put down a deposit include independent power providers Jupiter Power, Energy Vault and RWE Americas, who are connecting utilities, and increasingly data centers, with batteries. Peak also works with utilities directly including one unnamed customer in California, and is “in fairly advanced discussions with two of the major hyperscalers,” Mossburg said.
Not everyone is so optimistic about the technology. Lithium-ion batteries are still cheaper, at least up front.
“Sodium-ion batteries attracted considerable interest when lithium-ion battery prices surged in 2022,” said Isshu Kikuma, an energy storage analyst at BloombergNEF. Since then, he noted, those prices have come down.
And as with lithium-ion battery chemistry, Asian manufacturers already have an edge.
“Sodium-ion cells are currently exclusively manufactured on a commercial scale within China,” said Evan Hartley, a research manager at the Benchmark Minerals consulting firm. Large producers such as BYD and CATL are spending enormous amounts to research and develop new products, he said.
Other U.S.-based sodium-ion startups have floundered of late. Natron Energy canceled plans to produce sodium-ion battery cells in North Carolina last year after funding difficulties. Bedrock Materials, which was making sodium-ion batteries for EVs, also closed up shop, citing a bet on a lithium supply shortage that hadn’t panned out.
But Peak Energy’s model is different, Mossburg said. Unlike Natron, it won’t be trying to make the batteries that go into their systems at first. They’ll import them, initially from China and later from other countries in Asia.
“While working at Tesla, I saw the advantage of focusing on a great end product that customers want before you try to bite off more of the scope,” Mossburg said.
Last month, Peak announced a partnership with General Motors to develop their own cells.
Once up and running, Peak Energy’s Sacramento factory will make three to four battery systems per day, each filled with almost 8,000 battery cells. One system can power hundreds of homes for four hours, Mossburg said. Customers will deploy tens or hundreds in a single project, “basically creating a power-plant sized battery” that can store power and supply the grid when energy is expensive, or directly serve facilities like data centers.
Although sodium-ion batteries cost more than lithium ones, Mossburg said Peak Energy’s battery systems still save customers money: The technology does not heat up like lithium, so it eliminates the need for expensive cooling technology.
“Because lithium-ion needs to actively cool, you’re basically paying to refrigerate your batteries or using energy to refrigerate your batteries, and we don’t need any of that stuff,” said Mossburg.
The upshot is a battery that’s cheaper, quieter, and safer.
“Safety is a major advantage for sodium-ion batteries,” Kikuma said.
That could matter in California, where battery opposition has surged after a fire at a Moss Landing energy storage facility drove the evacuation of 1,200 residents and contaminated nearby wetlands.
California has typically been a hub of battery research and development, not manufacturing. Mossburg said Peak Energy, which also has offices in Colorado, chose Sacramento for its proximity to a talented workforce, a growing energy storage market and the company’s engineering teams in Burlingame. He said the factory would create 239 new jobs.
The company hasn’t received any federal clean energy tax credits, but it got a $10.5-million tax credit from the state of California.
While sodium-ion is likely to remain a small fraction of the global battery market, Kikuma said stationary energy storage is one of the fastest growing applications for sodium-ion batteries.
Mossburg sees Peak as being ahead in this corner of the market.
“Everybody from CATL to GM have sort of validated now what we’re doing,” he said. “The market is trying to catch up.”
Science
What’s the deal with … coffee enemas?
It seems like nothing is off limits these days in L.A.’s most woo-woo wellness scenes. From ayahuasca circles and mail-order ketamine lozenges to off-label peptide injections, IV drips and longevity treatments, there’s a seemingly infinite number of ways to look and feel better that people will swear by in this town. Coffee enemas — mostly for digestive issues, but also for a host of other emotional and physiological conditions — is on that alleged miracle menu, and far more common than I even realized before I started writing this article.
“Oh, I have a friend who does that,” “Oh, my cousin swears by it,” I began hearing from people as soon as I started looking for interviewees.
Reddit contains hundreds of anecdotes — both enthusiastic and cautionary — about coffee enemas, which involve a person, often on their own, but sometimes with the assistance of an alternative health practitioner, filling a bag with coffee fluid, inserting a tube into their rectum, and slowly allowing the liquid to be absorbed. “Beware of coffee enemas,” reads the subject line of a post from a woman who did them regularly for a decade and reports feelings of exhaustion, spaciness and cravings when she tries to stop. “Caffeine in any form only (temporarily) masks and provides salve toward bigger, unaddressed issue(s),” she writes.
In response, another user — a person with Stage 4 ovarian cancer — jumps in to defend the practice. “Let’s respect what we are all doing, whether we agree or not,” they write. “I am doing conventional [treatment] in conjunction with alternative (I believe there is a place for both). I haven’t felt this good since my diagnosis. I feel light, have never felt jittery and chemotherapy had me so constipated I would cry.”
Over the last couple of decades, the interest in digestive health has grown exponentially, prompted by research on the gut-brain connection. According to a report by Grand View Research, the global gut health market was valued at $60.31 billion in 2025 and is projected to reach $114.83 billion by 2033. The growing number of people who are quietly (and often devoutly) doing coffee enemas is a part of this larger trend, which also includes fasting, cleanses, colonics, probiotics, food allergy and stool tests, and a number of other products and services intended to address everything from irregular or uncomfortable bowel movements to energy levels and mood. But what’s the deal with coffee enemas? And are they actually good for you? We talked to a wide range of people with an equally wide range of opinions.
Five enemas a day? Inside the controversial Gerson therapy
The pro-enema Reddit user coping with Stage 4 cancer posted that they do three coffee enemas daily. They discovered the practice through Gerson, an institute founded in 1978 to promote a treatment plan initially developed for tuberculosis, and later for cancer, migraines and other chronic conditions, by German American physician Dr. Max Gerson in the 1930s. If you visit the Gerson Institute website, the supplies for a coffee enema — organic therapy blend coffee ($9.75) and the complete enema bucket kit with catheter ($19) — are listed in its store. It has clinics in Tijuana, Budapest and Shangri-La, China.
Nicole Ferrer-Clement, executive director of the Gerson Institute, says the treatment plan, referred to as the Gerson therapy, has four parts, with five coffee enemas per day being the first part and an essential component of the protocol. The other parts include a vegetarian, fat-free diet, three juices (carrot, carrot and apple, and a green juice) and supplements. The idea behind the coffee enemas, she says, is that compounds (theobromine, theophylline, caffeine) in coffee stimulate the liver to produce more bile, which helps carry toxins out of the body through the digestive tract. Ferrer-Clement says this is important for cancer patients, whose livers may already be compromised while processing toxins released during treatment. Even though many people reach out to Gerson about coffee enemas for general health and wellness and constipation, she says that’s not generally something they recommend. The therapy remains controversial among mainstream oncologists, in part because there are few rigorous clinical studies evaluating its efficacy.
“We want research on [coffee enemas], we’re happy and open to do that, if someone is going to fund it,” Ferrer-Clement says, estimating the institute has treated thousands of patients over the years.
In addition to using coffee enemas to treat cancer, the majority of users online report turning to them for constipation. Many anecdotes are from people who tried more conventional medicine for digestive issues and, from a place of desperation, decided to look elsewhere for solutions. Others, like Chevanni Davids, a 33-year-old South African man living in Bali, use them to maintain a general sense of well-being. Davids — who grew up in South Africa, where culturally it’s common for grandmothers to administer enemas to children in rural areas — does a coffee enema twice per month. He was introduced to the practice of enemas with coffee by someone he describes as a Brazilian grandmother or elder. He swears by the practice, saying it’s kept his bowel movements regular and his emotional state at an equilibrium. Davids warns against doing them too frequently, however. “The addiction is a thing,” he says, “because it feels so, so good. After you do it once, you’re going to say, ‘I’m going to do that tomorrow.’”
A doctor’s take
Unsurprisingly, given that most people tend to find coffee enemas after reports of being failed by Western medicine, mainstream gastroenterology is not on board with this practice. “Coffee enemas are based on the ill-conceived idea that you’re washing toxins out of your colon, but your colon is not an organ that clears toxins like the liver,” says Dr. Barry Zamost, a gastroenterologist who was in private practice in Long Beach for more than 40 years. “This just flies in the face of all logic and physiology that any doctor has learned for 100 years.”
Zamost remembers first hearing of coffee enemas decades ago when Michael Landon, an actor best known for his roles on “Little House on the Prairie” and “Bonanza,” decided to reject chemotherapy in favor of alternative treatments following a pancreatic cancer diagnosis in 1991. Over his four decades in private practice, Zamost says he frequently saw patients with constipation who were frustrated and trying alternate methods, but that oral therapies such as laxatives, supplements and prescription medications remain the most safe and effective treatments.
A review of case reports from nine people who self-administered coffee enemas also concluded that there’s insufficient evidence to prove that the practice is helpful, and that it could be harmful, to the colon. Zamost says he thinks it’s unlikely for someone to cause themselves serious harm by doing coffee enemas, although it’s happened. He also says that in rare cases that enemas — not with coffee — are appropriate for patients who are severely constipated to provide temporary relief. But, generally, he doesn’t see any benefit to using coffee. As for why people report loving them? That’s easy enough to explain, he says. “Everybody feels better after a bowel movement. So if you gave yourself an enema that really made you feel like you were emptied, you’ll feel good. It doesn’t mean your health is better.”
The takeaway
Coffee enemas are likely not harmful when done in moderation, but we don’t have much more than anecdotal evidence at this point to indicate that they’re helpful either.
Science
Contributor: The crucial medical question that AI can’t ever answer
One of us got a call last spring from a longtime friend. The story was familiar: two doctors, an MRI, an online AI tool, a stack of articles — and one anxious question. “Everything tells me something different. The AI says I might need surgery. What should I do?”
We believe there’s one key response to anyone in this all-too-common conundrum: “What matters most to you?”
There was a long pause.
That pause is one of the most important moments in modern healthcare — and it is exactly the question artificial intelligence is unable to address.
In our careers as physicians and researchers, we have found, clearly and repeatedly, that for many common conditions the medical evidence does not point to a single “right” answer. The biology is often close. What determines the success of an outcome is whether the choice fits the person making it.
Some patients with back pain want the fastest possible return to physically demanding work, even if it means surgery. Others want to avoid an operation at almost any cost, even if recovery takes longer. The scan may look the same. The lives behind the scan are not.
That insight is becoming critically important as artificial intelligence moves deeper into everyday health decisions.
In our research on AI and clinical decision-making, we’ve studied what happens when systems are trained to optimize medical outcomes but are blind to human values. In plain English, today’s AI is very good at telling you what usually works for people like you with similar demographics and medical histories. It is far less capable of understanding what you are trying to protect, avoid or prioritize.
This matters because some of the most common and most expensive medical decisions are not purely biological. Should someone with low-risk prostate cancer choose surgery, radiation or careful monitoring? Should a person with atrial fibrillation undergo a procedure or manage the condition with medication? Should a patient with chronic knee or back pain operate now or try months of physical therapy to see whether surgery can be avoided?
In these situations, the medical differences between options are often small or uncertain. What makes the biggest difference is whether the treatment aligns with the patient’s goals: tolerance for risk, willingness to undergo recovery, ability to adhere to long-term therapy or simply what kind of life they want to live.
AI systems can calculate probabilities. They cannot determine what those probabilities mean to a particular person.
In some respects, artificial intelligence may know more medicine than any individual physician. It can synthesize millions of scientific papers, clinical studies and patient records in seconds. Yet it knows remarkably little about the person sitting across from it. AI does not know a patient’s goals, fears, obligations, tolerance for risk or personal definition of a good outcome. And because it knows little about either the patient or the physician, it knows even less about the conversation between them — the place where facts, values and trust come together to produce the right decision for a particular person.
A second patient story brought this home. A retired teacher was referred after an AI-based symptom checker flagged a heart rhythm abnormality and “favored” an invasive procedure. The patient arrived frightened, convinced there was one correct path. When we talked, it became clear that what mattered most was avoiding a long recovery and staying healthy enough to travel to see grandchildren.
Medication and monitoring — less dramatic, but well-supported by evidence — fit those goals better. The AI wasn’t wrong. It just didn’t know what mattered.
This blind spot is not trivial. Roughly a quarter of U.S. healthcare spending flows through decisions in which patient preferences meaningfully affect outcomes. When those preferences are ignored — by people or by algorithms — care becomes misaligned. That can mean unnecessary procedures, poor adherence, regret and rising costs without better health.
So what should consumers do when an app, portal or “smart” tool recommends a course of action?
Start with three questions.
First: “Best for whom?” If a tool says one option is best, ask whether it means best on average — or best for someone with your priorities.
Second: “What does this system not know about me?”
AI can see lab values and imaging results. It cannot see your job, your family responsibilities, your fears or what you are trying to get back to.
Third: “What happens if I wait or choose differently?”
Many important medical decisions are not emergencies. When options are close, taking time to reflect is often part of good care.
Artificial intelligence is becoming a powerful partner in medicine. It can help explain options, surface evidence and reduce confusion. But it should inform human decisions, not replace them.
AI may know more medicine than any physician.
It knows far less about any patient.
And it knows least about the conversation between them.
The most important variable in your healthcare is not in any algorithm. It is you.
James N. Weinstein is a surgeon and former chief executive of Dartmouth Health. He is a clinical professor at Northwestern University’s Kellogg School of Management and global head of Health Futures at Microsoft, which develops AI systems. Ogan Gurel is a physician and assistant professor at the University of Texas at Arlington, where he researches AI, causal inference and patient decision-making.
-
Atlanta, GA5 minutes agoMosquitoes in Atlanta neighborhood test positive for West Nile Virus
-
Minneapolis, MN8 minutes agoMinneapolis, Hamel women accused of stealing millions in federal funds due in court Thursday
-
Indianapolis, IN13 minutes agoMan dies after car crashes into pole on near NW side
-
Pittsburg, PA20 minutes agoJohn Valentine wants to start a Downtown Chamber of Commerce
-
Augusta, GA23 minutes agoStabbing at Augusta McDonald’s leaves 1 hospitalized
-
Washington, D.C28 minutes agoMetro Red Line Summer Shutdown: Changes to shuttle bus service after concerns
-
Cleveland, OH35 minutes agoGuardians Lose Another Horrific Game
-
Austin, TX38 minutes agoAustin cannabis shop: THC ban would “hurt everybody”